earnings
confidence high
sentiment positive
materiality 0.60
Envoy Medical FY2024 revenue down $91K; clinical trial enrollment advances
Envoy Medical, Inc.
2025-Q1 EPS
reported -$0.29
vs consensus -$0.35
▲ beat
(+16.4%)
- Net revenues decreased $91K YoY; cash and equivalents were $5.5M as of Dec 31, 2024.
- R&D expenses increased $1.2M driven by headcount for Acclaim cochlear implant pivotal study.
- FDA approved pivotal trial; 6 of 10 planned first-stage participants enrolled and implanted.
- New CPT codes for fully implanted middle ear implants effective July 2025; Hearing Device Coverage Clarification Act reintroduced.
- G&A expenses down $438K reflecting lower professional fees post-business combination.